Affordable Access

Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives.

Authors
  • Scripture, Charity D1
  • Figg, William D
  • Sparreboom, Alex
  • 1 Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, MD, USA.
Type
Published Article
Journal
Current Neuropharmacology
Publisher
Bentham Science
Publication Date
Apr 01, 2006
Volume
4
Issue
2
Pages
165–172
Identifiers
PMID: 18615126
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Paclitaxel is an antineoplastic agent derived from the bark of the western yew, Taxus brevifolia, with a broad spectrum of activity. Because paclitaxel promotes microtubule assembly, neurotoxicity is one of its side effects. Clinical use of paclitaxel has led to peripheral neuropathy and this has been demonstrated to be dependent upon the dose administered, the duration of the infusion, and the schedule of administration. Vehicles in the drug formulation, for example Cremophor in Taxol, have been investigated for their potential to induce peripheral neuropathy. A variety of neuroprotective agents have been tested in animal and clinical studies to prevent paclitaxel neurotoxicity. Recently, novel paclitaxel formulations have been developed to minimize toxicities. This review focuses on recent advances in the etiology of paclitaxel-mediated peripheral neurotoxicity, and discusses current and ongoing strategies for amelioration of this side effect.

Report this publication

Statistics

Seen <100 times